AZR-MD-001 ophthalmic ointment showed positive 3-month safety and efficacy results for the treatment of meibomian gland dysfunction, according to a press release from Azura Ophthalmics.
The multicenter, double-masked, vehicle-controlled, parallel-group phase 2b study investigated AZR-MD-001 0.5%, applied twice weekly to the lower eyelid at bedtime, in 245 participants with meibomian gland dysfunction (MGD). The ointment met the co-primary endpoints of improvements in meibomian glands yielding liquid secretion (1.8 more open glands secreting meibum from baseline; P = .0004) and Ocular Surface